Brilinta (Ticagrelor) Patent Expiration, LOE Window & CMS Spending

Brilinta (Ticagrelor) by AstraZeneca: FDA Orange Book LOE 2036-07-27, 20 AB generics, $812.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN022433 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2036-07-27
Orange Book Patents (*PED Extensions)4 patents (2 *PED)
Active AB-Rated Generic Competitors20
2024 CMS Total Public Spend$812.0M
2024 Medicare Part D Spend$685.5M
2024 Medicaid Spend$126.6M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.